VANRAFIA DIN 02569590
Status: Approved
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: ATRASENTAN (ATRASENTAN HYDROCHLORIDE)
Health Canada record
| Active ingredient(s) | ATRASENTAN (ATRASENTAN HYDROCHLORIDE) 0.75 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C09XX OTHER AGENTS ACTING ON THE RENIN -ANGIOTENSIN SYSTEM |
| Original market date | |
| Current status date | 02-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37820 | 2026-07-02 | New Drug Submission (NDS) |